$170M franchise safe for another year

Gilead has pushed off a challenge to more than $170 million in reimbursements for at least another year.

Alphapharm has agreed to an injunction against it supplying Dencovir, its generic version of Gilead's HIV drug Descovy, in Australia. It includes not supplying Dencovir in any way, and withdrawing its application to list Dencovir on the PBS.

It's an important win for Gilead, since the listing of a generic of Descovy, which earned $8.8 million in pre-rebate R/PBS reimbursements in the financial year 2025-26, would see flow-on price reductions to three other Gilead medicines.

To see the whole article please log in.

James Quintana Pearce

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here